China's largest innovative drugmaker, developing oncology, metabolic and autoimmune drugs alongside a generics business.
China's largest innovative drugmaker, developing oncology, metabolic and autoimmune drugs alongside a generics business.
Sells to Chinese hospitals through a large sales force and also earns upfront and milestone payments when it licenses drugs to foreign companies. Over the past decade it has moved from mainly generics toward its own new drugs, which are now the main driver. It is controlled through a holding company associated with chairman Sun Piaoyang and added a Hong Kong listing in 2025.
In one line: China's Eli Lilly/Pfizer in miniature.
Moat: narrow (IP / patents, scale, brand). Largest domestic R&D pipeline and sales force among Chinese pharma, with growing licensing deals to global players.
Headquarters: Lianyungang, China · Founded: 1970 · Employees: 20,602
Size Jiangsu Hengrui Pharmaceuticals (600276.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $45.7B, the 35th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥46.90 on 18 Nov 2026.
Performance Over six months the shares fell 13.1%, against +16.9% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +14.0%); the operating margin is 27.4% (peer median 19.0%).
Valuation It trades at 33.4× forward earnings against a peer median of 19.0× (6th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 22.9 points above its cost of capital (6.8% WACC).
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥32.9B | CN¥31.4B | CN¥27.8B | CN¥22.6B | CN¥21.1B |
| Revenue growth | — | +13% | +23% | +7% | — |
| Gross profit | CN¥28.9B | CN¥26.7B | CN¥23.6B | CN¥18.7B | CN¥17.4B |
| EBITDA | n/a | CN¥8.96B | CN¥7.27B | CN¥4.90B | CN¥3.66B |
| Net income | CN¥8.88B | CN¥7.71B | CN¥6.34B | CN¥4.30B | CN¥3.91B |
| Free cash flow | CN¥6.11B | CN¥8.32B | CN¥5.51B | CN¥6.26B | -CN¥560M |
| Capital expenditure | CN¥3.92B | CN¥2.96B | CN¥1.97B | CN¥1.48B | CN¥1.99B |
| Total debt | CN¥422M | CN¥938M | CN¥669M | CN¥629M | CN¥1.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600276.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.2% | +7.0% | 4th lowest of 21 |
| 6-month return | -13.1% | +16.9% | lowest of 21 |
| Distance from 52-week high | -28.8% | -7.6% | 4th lowest of 21 |
| Revenue growth (TTM) | +6.0% | +14.0% | 7th lowest of 21 |
| Operating margin | 27.4% | 19.0% | 7th highest of 21 |
| Forward P/E | 33.4× | 19.0× | 6th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 13.4% | 7.6% | 5th most demanding of 18 |
| Growth delivered (Del g) | +2.7% | +8.9% | 5th lowest of 18 |
| Hurdle (Req g minus delivered) | +10.7 pp | -2.9 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +22.9 pp | +4.4 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% | +2.7% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Wuxi Apptec 2359.HK | Hong Kong | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% | +20.4% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Chugai Pharmaceutical 4519.T | Japan | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% | +9.8% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |